RxDoctor Payments Data

Heather Whittington

Family · Huntington, WVNPI 1124479043

Payments from drug & device makers

$4,149in general payments, 2019–2025

Across 294 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$822
  • Johnson & Johnson$371
  • Takeda Pharmaceuticals U.S.A., Inc.$193
  • Gilead$192
  • Bristol Myers Squibb$173
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,08298%
  • Education$672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,149 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$37,095
Medicare patients
315
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide101$78,434
RezdiffraResmetirom11$59,297
XifaxanRifaximin19$51,030
TrulancePlecanatide40$28,594
IbsrelaTenapanor Hcl11$22,128
ViberziEluxadoline14$21,618
Lubiprostone55$4,880
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine151$4,596
Dicyclomine Hcl181$4,354
Famotidine383$3,815
Mesalamine ErMesalamine13$3,513
Pantoprazole Sodium351$3,101
Lansoprazole18$3,094
Colestipol Hcl40$2,443
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi$1,268$100,052115 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$822$79,62459 claims
Madrigal PharmaceuticalsRezdiffra$30$59,29711 claims
Ardelyx, Inc.Ibsrela$153$22,12811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →